#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16078	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2100	759.8	0	.	n	.	0	C451T	SNP	451	451	C	685	685	T	987	T,C	914,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16078	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2100	759.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1418	1418	C	910	C,T	845,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16078	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2100	759.8	0	HET	.	.	.	C207T,A	.	207	207	C	441	441	C	893	C,T,A	682,156,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29126	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3580	810.1	0	.	n	.	0	T695C	SNP	695	695	T	1036	1036	C	944	C	875	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29126	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3580	810.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2312	2312	C	931	C,T,G	850,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29126	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3580	810.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2386	2386	A	961	A	904	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29126	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3580	810.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	2938	2938	C	879	C,A	820,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1994	folP	855	855	100.0	folP.l6.c30.ctg.1	1491	132.8	1	SNP	p	R229S	1	.	.	685	687	AGC	981	983	AGC	201;202;201	A;G;C	194;190;187	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5760	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3378	169.5	1	SNP	p	S91F	1	.	.	271	273	TTC	649	651	TTC	185;185;184	T;T;C,A,G	173;174;169,1,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5760	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3378	169.5	1	SNP	p	D95G	1	.	.	283	285	GGC	661	663	GGC	184;186;185	G;G,A;C	172;174,1;177	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5760	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3378	169.5	1	SNP	p	G95N	0	.	.	283	285	GGC	661	663	GGC	184;186;185	G;G,A;C	172;174,1;177	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1564	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1205	128.0	1	SNP	p	G45D	0	.	.	133	135	GGC	475	477	GGC	214;210;214	G;G;C,G	195;190;193,1	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	800	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1105	72.0	0	.	n	.	0	A197.	DEL	197	197	A	632	632	A	199	A	193	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6130	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2844	214.0	1	SNP	p	D86N	0	.	.	256	258	GAC	457	459	GAC	233;233;235	G;A;C	206;203;213	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6130	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2844	214.0	1	SNP	p	S87R	1	.	.	259	261	CGT	460	462	CGT	235;232;233	C;G;T	212;209;206	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6130	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2844	214.0	1	SNP	p	R87W	0	.	.	259	261	CGT	460	462	CGT	235;232;233	C;G;T	212;209;206	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6130	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2844	214.0	1	SNP	p	R87I	0	.	.	259	261	CGT	460	462	CGT	235;232;233	C;G;T	212;209;206	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6130	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2844	214.0	1	SNP	p	S88P	0	.	.	262	264	TCC	463	465	TCC	235;236;238	T;C;C,G	209;210;211,1	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4128	parE	1986	1986	99.95	parE.l6.c30.ctg.1	2692	152.7	0	.	p	.	0	R30C	NONSYN	88	90	CGC	402	404	TGC	183;181;179	T;G;C	171;169;167	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4128	parE	1986	1986	99.95	parE.l6.c30.ctg.1	2692	152.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1542	1544	GGC	195;194;194	G;G;C	169;170;168	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	4052	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2361	170.7	1	SNP	p	A311V	0	.	.	931	933	GCC	1200	1202	GCC	213;213;212	G;C,G;C	197;194,1;194	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4052	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2361	170.7	1	SNP	p	I312M	1	.	.	934	936	ATG	1203	1205	ATG	214;213;215	A;T;G	197;194;196	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4052	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2361	170.7	1	SNP	p	T316P	0	.	.	946	948	ACC	1215	1217	ACC	215;218;221	A;C;C	199;205;205	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4052	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2361	170.7	1	SNP	p	V316T	1	.	.	946	948	ACC	1215	1217	ACC	215;218;221	A;C;C	199;205;205	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4052	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2361	170.7	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1716	1718	ACC	213;215;217	A;C;C	194;200;201	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4052	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2361	170.7	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1770	1772	GCG	213;211;214	G;C;G	197;197;197	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4052	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2361	170.7	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1770	1772	GCG	213;211;214	G;C;G	197;197;197	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4052	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2361	170.7	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1893	1895	GGT	181;180;179	G;G;T	166;167;159	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4052	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2361	170.7	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1902	1904	AGC	179;179;178	A;G;C	158;159;153	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4052	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2361	170.7	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1920	1922	CCG	162;166;163	C,G;C,G;G,GGC	110,4;118,3;113,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6064	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	3142	192.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1718	1720	CCG	241;239;239	C;C;G,T	205;210;205,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2152	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1745	122.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	532	532	C	154	C	136	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	3182	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	1465	215.1	1	SNP	p	G120K	1	.	.	358	360	AAG	645	647	AAG	257;256;260	A;A;G,A	232;236;232,2	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	3182	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	1465	215.1	1	SNP	p	A121N	1	.	.	361	363	AAC	648	650	AAC	259;260;261	A;A;C	236;239;238	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	3182	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	1465	215.1	1	SNP	p	N121D	0	.	.	361	363	AAC	648	650	AAC	259;260;261	A;A;C	236;239;238	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12090	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4826	249.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1286	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1056	120.8	1	SNP	p	V57M	1	.	.	169	171	ATG	584	586	ATG	272;269;270	A;T;G	256;253;253	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
